Business
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical compan
About this update from Journey Medical Corporation
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hjjUQ.iXZdhdLwOzj17HjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hjjUQ.iXZdhdLwOzj17HjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million ","length":103,"tagName":"p"},{"type":"text","content":"Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026","length":76,"tagName":"p"},{"type":"text","content":"Cash position increased to $27 million, driven by strong financial performance","length":78,"tagName":"p"},{"type":"text","content":"Company to hold conference call today at 4:30 p.m. ET","length":53,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2026.","length":440,"tagName":"p"},{"type":"text","content":"Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2026 is off to a strong start, as we delivered solid revenue growth and cash generation in the first quarter of the year. Prescription demand and payer coverage for Emrosi® continue to increase, with the product’s differentiated clinical profile gaining traction as we establish Emrosi® as the best-in-class oral treatment for patients suffering from rosacea. Increasing refill rates and a growing number of Emrosi® prescribers are also building momentum behind the bra...